The multiplexed platform will identify new indications for drug candidates.

Melior Discovery’s theraTRACESM indications discovery platform will be used to identify possible new indications for multiple Johnson & Johnson Pharmaceutical Research & Development (J&JPRD) drug candidates.

The theraTRACE platform is a multiplexed set of integrated in vivo models that systematically test the potential efficacy of compounds across a large number of disease models. It reduces the time, amount of test compound, and number of test subjects needed while also reducing the number of false positive results, according to the companies.

Previous articleAbraxis Gains Immunotherapeutic Candidates and Assay Systems from Buck Institute
Next articleBioServe and Phenomenome Provide Colorectal Cancer Diagnostic Technology